DR. MICHAEL JOHN MANYAK, MD
Urology at Blaine Dr, Bethesda, MD
License number
Maryland MD13454
Category
Radiology
Type
Urology
Address
Address
2322 Blaine Dr, Bethesda, MD 20815
Phone
(301) 588-1881
Personal information
See more information about MICHAEL JOHN MANYAK at radaris.comName
Address
Phone
2322 Blaine Dr, Bethesda, MD 20815
2322 Blaine Dr, Chevy Chase, MD 20815
1401 Blair Mill Rd, Silver Spring, MD 20910
Professional information
Non-Steroidal Anti-Inflammatory Agent Therapy For Epithelial Cell Cancer
US Patent:
6335321, Jan 1, 2002
Filed:
Apr 21, 2000
Appl. No.:
09/556468
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
Assignee:
The George Washington University Medical Center - Washington DC
International Classification:
A61K 3800
US Classification:
514 21, 514 12
Abstract:
The invention relates to methods for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relates to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A.
Pharmaceutical Compositions, Methods, And Kits For Treatment And Diagnosis Of Lung Cancer
US Patent:
6509316, Jan 21, 2003
Filed:
Dec 9, 1997
Appl. No.:
08/987505
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
Assignee:
George Washington University - Washington DC
International Classification:
A61K 3514
US Classification:
514 12, 514 21, 530350, 530352, 530386, 530850, 530851, 530853
Abstract:
The present invention relates to pharmaceutical compositions, methods and kits that provide for the early diagnosis and treatment of lung cancer. More particularly, the present invention relates to pharmaceutical compositions containing uteroglobin for preventing or inhibiting metastasis of lung tumor cells and methods of using the same to prevent or inhibit metastasis of lung tumor cells. The present invention also relates to methods and kits for early diagnosis of metastatic lung cancer by assaying for uteroglobin and comparing the results against control cells. The present invention also relates to methods and kits for detection of metastatic lung cancer by assaying for the presence of an aberrant form of uteroglobin.
Use Of Uteroglobin Expression As A Molecular Marker For Prostatic Intraepithelial Neoplasia
US Patent:
5935860, Aug 10, 1999
Filed:
Jun 5, 1996
Appl. No.:
8/658796
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
Assignee:
The George Washington University - Washington DC
International Classification:
G01N 3348
US Classification:
436 64
Abstract:
The invention relates to methods for identifying prostatic intraepithelial neoplasia by determining the uteroglobin concentration in a tissue sample.
Dr. Michael J Manyak, Chevy Chase MD - MD (Doctor of Medicine)
Specialties:
Urology
Address:
2322 Blaine Dr, Chevy Chase 20815
(301) 588-1881 (Phone), (202) 223-1024 (Fax)
(301) 588-1881 (Phone), (202) 223-1024 (Fax)
Certifications:
Urology, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of The East / Ramon Magsaysay Memorial Medical Center
Booth Meml Med Center
Graduated: 1982
George Washington University
Graduated: 1985
National Canc Institute
Graduated: 1988
University of The East / Ramon Magsaysay Memorial Medical Center
Booth Meml Med Center
Graduated: 1982
George Washington University
Graduated: 1985
National Canc Institute
Graduated: 1988
Methods For Inhibiting Metastasis
US Patent:
6358915, Mar 19, 2002
Filed:
Dec 9, 1997
Appl. No.:
08/987502
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
Assignee:
George Washington University - Washington DC
International Classification:
A61K 3800
US Classification:
514 2, 514 45, 514 12, 514 15, 436501, 530350, 536 235
Abstract:
The invention relates to methods for determining degree of integrin-mediated maintenance of cell invasive capacity of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine degree of integrin-mediated maintenance of cell invasive capacity of epithelial derived tumors, particularly prostatic, breast, and lung cancers. In these regards, the invention relates to determining protein or mRNA of effectors of integrin-mediated maintenance of cell invasive capacity, particularly uteroglobin protein or mRNA, or to gauge degree of integrin-mediated maintenance of cell invasive capacity of prostatic, breast, or lung tumors. The invention also relates to methods and compositions, such as uteroglobin, which specifically bind to integrin and are effectors of integrin-mediated maintenance of tumor cell invasive capacity and thus inhibit metastasis.
Uteroglobin Gene Therapy For Epithelial Cell Cancer
US Patent:
6395715, May 28, 2002
Filed:
Apr 21, 2000
Appl. No.:
09/556467
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
Assignee:
The George Washington University Medical Center - Washington DC
International Classification:
A01N 4304
US Classification:
514 44, 424 932, 4353201
Abstract:
The present invention provides a novel method for inhibiting the growth of tumor cells of epithelial origin, comprising administration of a functional uteroglobin gene in a gene therapy regime, so as to inhibit growth of the tumor cells.
Uteroglobin Therapy For Epithelial Cell Cancer
US Patent:
6316416, Nov 13, 2001
Filed:
Feb 25, 2000
Appl. No.:
9/512385
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
International Classification:
A61K 3800, A61K 3816
US Classification:
514 21
Abstract:
The invention relates to method for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relate to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors.
The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2.
Determining Invasiveness Of Prostatic Adenocarcinoma
US Patent:
5830640, Nov 3, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/486203
Inventors:
Steven R. Patierno - Falls Church VA
Michael Manyak - Chevy Chase MD
Michael Manyak - Chevy Chase MD
Assignee:
George Washington University - Washington DC
International Classification:
C12Q 100, G01N 3353, C07K 1600
US Classification:
435 4
Abstract:
The invention relates to methods for determining metastatic potential of tumors and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In this regard the invention relates to determining protein or mRNA of effectors of arachadonic acid release to gauge metastatic potential, particularly uteroglobin protein or mRNA to determine metastatic potential of prostatic tumors.
The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2. More particularly in this regard, the invention relates to uteroglobin or muteins, peptide analogs or mimetics of uteroglobin and lipocortins or muteins, peptide analogs, or mimetics of lipocortins that inhibit metastasis. Especially it relates to methods and compositions in which uteroglobins, particularly human uteroglobins, inhibit or prevent metastasis of cancer, particularly prostatic cancer.
Kit For Indentifying Prostatic Intraepithelial Neoplasia (Pin)
US Patent:
6054320, Apr 25, 2000
Filed:
Nov 7, 1997
Appl. No.:
8/966196
Inventors:
Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD
Michael J. Manyak - Chevy Chase MD
Assignee:
George Washington University - Washington DC
International Classification:
G03G 1504
US Classification:
436 64
Abstract:
The invention relates to methods for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relates to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2.
Methods And Compositions For Inhibiting Metastasis Of Epithelial Cell-Derived Cancers
US Patent:
5696092, Dec 9, 1997
Filed:
Mar 7, 1995
Appl. No.:
8/400084
Inventors:
Steven R. Patierno - Falls Church VA
Michael Manyak - Chevy Chase MD
Michael Manyak - Chevy Chase MD
Assignee:
George Washington University - Washington DC
International Classification:
A61K 3817
US Classification:
514 21
Abstract:
The present invention relates to methods and compositions that prevent or inhibit metastases of cancers of epithelial cell origin, especially human prostate cancers. A particular aspect of the invention relates to methods and compositions that inhibit arachidonic acid release in cells of these cancers and inhibit or prevent metastasis. In one aspect in this regard, the invention particularly relates to methods and compositions that inhibit phospholipase A. sub. 2 that mediates arachidonic acid release in the cancer cells. In a further aspect, the invention relates to methods and compositions wherein uteroglobin, uteroglobin muteins, peptide analogs of uteroglobins, lipocortins, lipocortin muteins and peptide analogs of lipocortins inhibit arachidonic acid release by cancer cells. In this regard, the invention relates especially to uteroglobins, particularly human uteroglobins.